Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Baxter
Healthtrust
Deloitte
Farmers Insurance
Colorcon

Generated: July 23, 2019

DrugPatentWatch Database Preview

Patent: 7,198,789

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,198,789
Title:Methods and compositions for modulating interleukin-21 receptor activity
Abstract: Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (\"IL-21R\" or \"MU-1\"), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.
Inventor(s): Carter; Laura (Medford, MA), Carreno; Beatriz (Acton, MA), Lowe; Leslie D. (Sudbury, MA), Whitters; Matthew J. (Hudson, MA), Dunussi; Kyri (Belmont, MA), Collins; Mary (Natick, MA), Ma; Margery (W. Roxbury, MA), Young; Deborah A. (Melrose, MA), Witek; JoAnn S. (Acton, MA), Larsen; Glenn (Sudbury, MA), Kasaian; Marion T. (Charlestown, MA), Donaldson; Debra D. (Medford, MA), Unger; Michelle (Chapel Hill, NC)
Assignee: Genetics Institute, LLC (Cambridge, MA)
Application Number:10/264,634
Patent Claims:see list of patent claims

Details for Patent 7,198,789

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31 ➤ Sign Up Genetics Institute, LLC (Cambridge, MA) ➤ Sign Up RX search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31 ➤ Sign Up Genetics Institute, LLC (Cambridge, MA) ➤ Sign Up RX search
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 003 2001-11-14 ➤ Sign Up Genetics Institute, LLC (Cambridge, MA) ➤ Sign Up RX search
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 002 2001-11-14 ➤ Sign Up Genetics Institute, LLC (Cambridge, MA) ➤ Sign Up RX search
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 001 2001-11-14 ➤ Sign Up Genetics Institute, LLC (Cambridge, MA) ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 7,198,789

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 0185792 Aug 21, 2003
World Intellectual Property Organization (WIPO) 0185792 May 23, 2002
World Intellectual Property Organization (WIPO) 0185792 Nov 15, 2001
World Intellectual Property Organization (WIPO) 03028630 Apr 10, 2003
World Intellectual Property Organization (WIPO) 03028630 Mar 18, 2004
Country Patent Number Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
Teva
AstraZeneca
US Army
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.